Study of HCD122 in Adults With Non-Hodgkin's or Hodgkin's Lymphoma Who Have Progressed After at Least Two Prior Therapies
- Registration Number
- NCT00670592
- Lead Sponsor
- Novartis Pharmaceuticals
- Brief Summary
This study is to evaluate the highest tolerated dose, safety and activity of HCD122 in adults with non-Hodgkin's or Hodgkin's lymphoma who have received at least two prior therapies.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- 111
Inclusion Criteria
Not provided
Exclusion Criteria
Not provided
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- SINGLE_GROUP
- Arm && Interventions
Group Intervention Description HCD122 HCD122 -
- Primary Outcome Measures
Name Time Method Primary endpoints (phase I) - Incidence rate of DLT and AE 2 years Primary endpoint (phase II) - Response rate 2 years
- Secondary Outcome Measures
Name Time Method Adverse events by frequency, severity, and duration; pharmacokinetics; immunogenicity; response duration; time to progression 2 years
Trial Locations
- Locations (6)
Dana Farber Cancer Institute SC-5
🇺🇸Boston, Massachusetts, United States
Northwestern University
🇺🇸Chicago, Illinois, United States
University of Texas/MD Anderson Cancer Center Dept.ofMDAndersonCancerCtr(3)
🇺🇸Houston, Texas, United States
St. Francis Cancer Research Foundation Dept.ofSt.FrancisCancerRes.(2)
🇺🇸Beech Grove, Indiana, United States
Novartis Investigative Site
🇬🇧London, United Kingdom
Wake Forest University Baptist Medical Center Dept. of Industry Research (2)
🇺🇸Winston-Salem, North Carolina, United States